Plain-English translation of NCT06016920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , given as injections into your muscles, combined with —a standard immunotherapy treatment. Researchers want to find the best dose of this medication and learn whether it can help shrink tumors and improve survival in people with advanced head and neck cancer caused by the HPV virus.
People with advanced HPV-related head and neck cancer have limited treatment options, and many don't respond well enough to alone. This trial exists to see whether adding —a medication designed to train your immune system to attack cancer cells—can work better when combined with standard treatment.
You likely qualify if…
You likely don't qualify if…
You will receive muscle injections of at escalating doses (the first group gets 3 mg, then 6 mg, then 9 mg, depending on safety) plus intravenous infusions of every three weeks. The trial lasts at least 48 weeks of combination treatment, with regular visits for blood tests, imaging scans, and monitoring of side effects. After 48 weeks, you may continue on alone at your doctor's discretion.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Czechia
France